{
  "figure_1": "The PRISMA flowchart of literature search and study eligibility strategy",
  "figure_2": "Pooled pCR outcome of TA-treated Asian breast cancer patients according to molecular subtypes. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in NAC TA-treated breast cancer patients between (A) HER2E and luminal-like; (B) HER2E and luminal A; (C) HER2E and luminal B; (D) HER2E and luminal, combined; and (E) TNBC and luminal-like; (F) TNBC and luminal A; (G) TNBC and luminal B; and (H) TNBC and luminal, combined. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
  "figure_3": "Pooled pCR outcome of TP-treated Asian breast cancer patients according to molecular subtypes. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in NAC TP-treated Asian breast cancer patients between (A) HER2E and luminal-like; (B) HER2E and luminal A; (C) HER2E and luminal B; (D) HER2E and luminal, combined; (E) Luminal B and luminal A; (F) TNBC and luminal A; (G) TNBC and luminal B. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
  "figure_4": "Pooled pCR outcome of NAC-treated Asian breast cancer patients according to molecular subtypes and biomarkers. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in (A) NAC TP-treated Asian breast cancer patients between TNBC and luminal, combined; (B) between Asian TNBC patients treated with NAC TP and TA; Asian breast cancer patients treated with anthracycline-based chemotherapy with (C) ER; (D) PR; and (E) HER2 biomarkers; (F) Asian breast cancer patients treated with taxane-based chemotherapy and HR biomarker; (G) Asian breast cancer patients treated with TA and ER biomarker. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
  "figure_5": "Pooled pCR outcome of TA-treated Asian breast cancer patients according to biomarkers. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in NAC TA-treated breast cancer patients in biomarkers (A) PR; (B) HR; (C) HER2; (D) nm23-H1; and (E) CK5/6. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
  "figure_6": "Pooled pCR outcome of NAC-treated Asian breast cancer patients according to biomarkers. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in (A) NAC TA-treated breast cancer patients in biomarkers Ki-67; NAC TP-treated breast cancer patients in biomarkers (B) ER; (C) PR; (D) HR; and (E) Ki-67. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
  "figure_7": "Pooled pCR outcome of NAC-treated Asian patients according to biomarkers and genetic variation. Forest plots describing the random effect ORs and 95% CIs from studies assessing the (A) Association of pCR outcome in NAC TP-treated Asian breast cancer patients in HER2; (B) Association between pCR in Asian patients with HER2+ biomarker treated with NAC TP and TA; and (C) Association of pCR outcome in NAC TA-treated Asian breast cancer patients in PIK3CA gene. I2 and p-value for X2 of heterogeneity are reported for each group analysis"
}